Innovative TEECAD Technology to be Unveiled at ASE 2025 Conference in Nashville

TEECAD Technology Showcased at ASE 2025

The upcoming American Society of Echocardiography (ASE) 2025 conference will feature a pivotal presentation from Visura Technologies, Inc., a leader in medical device innovation. On September 7th, at 9:45 a.m. in Nashville, the company will unveil data from its TEECAD product registry, emphasizing the state-of-the-art visualization solutions designed to enhance the safety and efficiency of transesophageal echocardiogram (TEE) procedures.

Background on Visura Technologies and TEECAD

Visura Technologies is committed to developing advanced technologies that improve clinical outcomes in cardiology. Their flagship product, the TEECAD system, is a disposable camera specifically engineered for real-time visualization during TEE intubation. This device aims to address the challenges associated with conventional TEE intubations, which traditionally rely on tactile feedback and often lead to complications such as esophageal injury or failed intubation.

The TEECAD camera connects seamlessly with existing TEE probe systems, offering clinicians valuable insights into the esophageal inlet and the surrounding anatomical structures during the intubation process. This innovation not only reduces the risks associated with TEE procedures but also enhances the overall efficiency of the intubation.

The Study and Findings

The presentation will highlight findings from TEECAD's clinical usage on approximately 200 TEE patients, showing the device's capability to facilitate effective navigation of the esophageal inlet without adverse events. The data reflects the experiences gathered from over 68 physicians across 16 heart centers in the United States, spanning from May 2024 to March 2025.

During this period, procedural and user data were collected through a standardized questionnaire, capturing insights from 29 attending physicians and 39 fellows. The scenarios conducted included TEE procedures in the echo laboratory, Intensive Care Unit (ICU), and operating room, showcasing the versatility of the TEECAD device. The systematic collection of data is integral to both validating the device’s effectiveness and shaping the future of TEE practices.

Expert Insights

Visura will host a series of physician-led discussions at their booth, emphasizing the integration of the TEECAD system into routine clinical workflows. Notably, Dr. Omar Khalique and Dr. Sunil Mankad have highlighted the clinical necessity of adopting TEECAD, particularly for patients with additional challenges like frailty or difficulty swallowing. Their observations underscore the potential of TEECAD to offer dynamic visualization, ensuring practitioners can swiftly adjust approaches during intubation.

Chad Olinger, DO, President at Metropolitan Heart and Vascular Institute, further emphasizes the need for enhanced visualization in TEE. He advocates for the consistent push towards updating clinical guidelines to incorporate more technology-driven approaches such as TEECAD, which promise to mitigate procedure-related complications effectively.

Looking Ahead: The Future of TEE with TEECAD

At the ASE 2025, Visura Technologies will not only present their findings but will also participate in invite-only discussions during the ASE Industry Round Table (IRT) meeting. Here, leading clinicians will collaborate to envision the future of an integrated TEE clinical infrastructure. This platform is essential for exploring collaborative opportunities and disseminating best practices in cardiology.

With over 1.7 million TEE procedures performed in the United States annually and an annual growth rate of 10%, advances like TEECAD are poised to redefine the clinical landscape significantly. The potential to reduce the chance of complications and enhance procedural success is paramount as the medical community looks to improve patient safety and outcomes.

For those attending ASE 2025, the TEECAD presentation promises to deliver cutting-edge insights and foster discussions that could reshape TEE procedures moving forward.

Conclusion

The imminent introduction of TEECAD technology at ASE 2025 illustrates the ongoing commitment of Visura Technologies to advancing cardiology practices. As the company continues to push boundaries in medical visualization, the healthcare industry can expect transformative solutions in providing care to patients undergoing TEE procedures.

For more information about TEECAD and its applications, visit Visura Technologies.